Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Gritstone bio, Inc. (GRTS) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million"
08/15/2023 8-K Other Events  Interactive Data
08/09/2023 8-K Quarterly results
Docs: "Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates -- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE in first-line metastatic microsatellite-stable colorectal cancer ; preliminary efficacy data expected in 1Q 2024 -- -- Gritstone partnering with Friends of Cancer Research on Friends’ ctDNA for Monitoring Treatment Response Project, a collaborative research initiative to inform use of ctDNA change as surrogate for survival benefit -- -- Publication in Nature Communications of interim CORAL-BOOST results highlights the potential of Gritstone’s self-amplifying mRNA candidates to serve as next-generation vaccine against SARS-CoV-2 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $122.3 million as ..."
05/11/2023 8-K Quarterly results
Docs: "Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates -- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE to date; 71 of 80 patients enrolled as of May 10, 2023-- -- Gritstone prioritizing GRANITE; expanding Phase 2 from 80 to 100 patients, enrollment completion expected in 3Q2023, preliminary data on approximately 50 patients expected in 1Q2024 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $153.2 million as of March 31, 2023 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, CALIF."
04/06/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "First Amendment to Loan and Security Agreement, by and among Gritstone bio Inc., as borrower, Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), Hercules Capital, Inc., Hercules Capital Funding Trust 2022-1, each as a Lender, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the several banks and other financial institutions or entities form time to time party to the Loan and Security Agreement",
"First Amendment to Loan and Security Agreement, by and among Gritstone bio Inc., as borrower, Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), Hercules Capital, Inc., Hercules Capital Funding Trust 2022-1, each as a Lender, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the several banks and other financial institutions or entities form time to time party to the Loan and Security Agreement"
03/09/2023 8-K Quarterly results
Docs: "Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates -- Preliminary data from GRANITE Phase 2/3 study remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals from “off-the-shelf” vaccine program consistent with those from GRANITE; randomized study of SLATE in patients with newly-diagnosed metastatic cancer to initiate in 2H 2023 -- -- Clinical evidence building for differentiation of self-amplifying mRNA as a potential next-gen mRNA platform in infectious disease -- -- Cash, cash equivalents, marketable securities, and restricted cash of $185.2 million as of December 31, 2022 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, CALIF."
01/09/2023 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/25/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
07/22/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition  Interactive Data
01/04/2022 8-K Investor presentation
Docs: "Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1study Evaluating a T Cell-Enhanced Self-Amplifying mRNA Vaccine Against COVID-19",
"Presentation Slides January 2022"
12/17/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/29/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "LEASE Between RREF II Kenmore Lessor III LLC and RREF II Kenmore Lessor IV LLC, as Landlord and Gritstone bio, Inc., as Tenant At The Beacon Building Boston, Massachusetts 1 EXHIBIT 1, SHEET 1 The Beacon Building 650-660 Beacon Street, 648 Beacon Street Boston, Massachusetts Effective Date: September 23, 2021 Tenant: Gritstone bio, Inc., a Delaware Corporation Tenant Mailing Address: 5959 Horton Street, Suite 300 Emeryville, CA 94608 From and after the Term Commencement Date: 660 Beacon Street Boston, Massachusetts Attn: Office Manager With copies of legal notices to: 5959 Horton Street, Suite 300 Emeryville, CA 94608 Attn: General Counsel Landlord: Collectively below), RREF II Kenmore Lessor III LLC , a Delaware limited liability company, and RREF II Kenmore Lessor IV LLC , a Delaware lim...",
"FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE is entered into as of this 21st day of September, 2021, by and between BMR-Sidney Research Campus LLC, a Delaware limited liability company , and Gritstone Bio, Inc. , a Delaware corporation . RECITALS A. WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of February 11, 2016 , whereby Tenant leases certain premises from Landlord located at 40 Erie Street in Cambridge, Massachusetts ; B. WHEREAS, Tenant has requested and Landlord has agreed to extend the term of the Existing Lease; and C. WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated. AGREEMENT NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises conta...",
"Third Amendment to License Agreement This Third Amendment to License Agreement is made as of September 21, 2021, by and between Gritstone bio, Inc. and MIL 21E, LLC . WHEREAS, Licensor and Licensee are parties to a certain License Agreement dated September 6, 2018, as amended by that certain First Amendment to License Agreement dated July 11, 2019, as amended by that certain Second Amendment to License Agreement date May 20, 2020 ; WHEREAS, Licensee warrants and represents that, to the best of its knowledge, Licensor has fulfilled its obligations under the License Agreement and is not in default of any covenants or obligations contained in the License Agreement; WHEREAS, Licensor and Licensee desire to amend the License Agreement in certain respects as set forth herein; and, WHEREAS, all ..."
09/17/2021 8-K Quarterly results
08/17/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program Against SARS-CoV-2 Variants of Concern"
06/23/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
02/01/2021 8-K Quarterly results
01/29/2021 8-K Quarterly results
01/22/2021 8-K Entry into a Material Definitive Agreement, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
12/30/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Securities Purchase Agreement",
"Securities Purchase Agreement"
12/28/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Pre-Funded Warrant",
"Securities Purchase Agreement"
12/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
10/23/2020 8-K Other Events  Interactive Data
07/13/2020 8-K Quarterly results
06/19/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy